Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta’s research and development is currently focused on three disease targets: Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH)/PBC and Respiratory Syncytial Virus (RSV).

TypePublic
HQWatertown, US
Founded1998
Size (employees)89 (est)+18%
Websiteenanta.com
Enanta Pharmaceuticals was founded in 1998 and is headquartered in Watertown, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Enanta Pharmaceuticals

Jay R. Luly

Jay R. Luly

President, Chief Executive Officer and Director
Yat Sun Or

Yat Sun Or

Senior Vice President, Research & Development and Chief Scientific Officer
Paul J. Mellett

Paul J. Mellett

Senior Vice President, Finance & Administration and Chief Financial Officer
Show more

Enanta Pharmaceuticals Office Locations

Enanta Pharmaceuticals has an office in Watertown
Watertown, US (HQ)
500 Arsenal Street
Show all (1)
Report incorrect company information

Enanta Pharmaceuticals Financials and Metrics

Enanta Pharmaceuticals Revenue

Enanta Pharmaceuticals's revenue was reported to be $102.81 m in FY, 2017
USD

Revenue (Q3, 2018)

139.4 m

Net income (Q3, 2018)

44.5 m

EBIT (Q3, 2018)

53.9 m

Market capitalization (19-Sep-2018)

1.8 b

Closing stock price (19-Sep-2018)

92.1

Cash (30-Jun-2018)

42.5 m
Enanta Pharmaceuticals's current market capitalization is $1.8 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

32.1 m47.7 m160.9 m88.3 m102.8 m

Revenue growth, %

49%237%(45%)

General and administrative expense

17 m20.7 m

R&D expense

40.5 m57.5 m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q2, 2018Q3, 2018

Revenue

42.1 m77.5 m57.4 m11.6 m48.4 m13 m14 m10.4 m9 m82.2 m139.4 m

General and administrative expense

2.6 m2.8 m3.4 m3.6 m3.8 m4.4 m4.3 m4.9 m5.5 m11.5 m17.6 m

R&D expense

4.6 m4.5 m5.4 m6.3 m9 m9.1 m10.8 m12.5 m13 m39.4 m67.9 m

Operating expense total

7.2 m7.3 m8.8 m9.9 m12.9 m13.6 m15.1 m17.5 m18.5 m50.9 m85.5 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

8.9 m30.7 m21.7 m16.6 m65.7 m

Accounts Receivable

808 k1.7 m15.3 m12.8 m10.6 m

Inventories

1.6 m1.6 m8.3 m9.2 m3.5 m

Current Assets

104.7 m108 m170.6 m232.2 m237.8 m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q2, 2018Q3, 2018

Cash

26.4 m34.1 m25.8 m19.8 m46.2 m56.4 m24.8 m20.6 m19.2 m66.9 m42.5 m

Accounts Receivable

399 k76.6 m7.1 m11.7 m17.9 m13 m14 m10.4 m9 m44 m57.3 m

Current Assets

111.7 m185.1 m177.8 m172.6 m209 m242.7 m241.8 m224.1 m190.6 m305.7 m339.9 m

PP&E

1.6 m1.9 m2.3 m2.6 m7.9 m7.7 m7.5 m8.3 m8.5 m8.6 m8.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

9.6 m34.4 m79 m21.7 m17.7 m

Depreciation and Amortization

221 k352 k639 k1.7 m2.1 m

Inventories

(307 k)568 k(6.7 m)(964 k)3.5 m

Accounts Payable

115 k399 k(543 k)1.5 m633 k
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q2, 2018Q3, 2018

Net Income

39.5 m42 m70.8 m73.2 m26.2 m24.5 m23.5 m(5 m)(10.4 m)24.2 m44.5 m

Depreciation and Amortization

242 k129 k270 k435 k339 k772 k1.2 m493 k1 m1.2 m1.9 m

Accounts Payable

(190 k)(1.3 m)488 k(332 k)149 k1.2 m677 k(1.3 m)688 k565 k1.4 m

Cash From Operating Activities

25.1 m(5.6 m)93.3 m79 m30 m40 m37.9 m3.1 m143 k(3.2 m)879 k
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Enanta Pharmaceuticals Company Life and Culture

Report incorrect company information